Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenyatta Mireku

Dermatology Lawrenceville, GA Medical Doctor

NPI 1740600048 CMS profile 4221538

771 Old Norcross Rd Ste 260, Lawrenceville, GA 30046

Open in the dashboard

General payments

$53,940

695 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenyatta Mireku of Lawrenceville, GA is reported in the CMS Open Payments database as having received $53,940 across 695 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,091 170
2024 General $14,769 160
2023 General $2,887 141
2022 General $2,114 90
2021 General $851 37
2020 General $511 16
2019 General $1,717 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenyatta Mireku
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Kenyatta Mireku were reported at $31,091. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Kenyatta Mireku Dermatology median Middle half National median
2019 $1,717 $454 $129–$1,240 $163
2020 $511 $235 $81–$756 $114
2021 $851 $377 $108–$1,108 $132
2022 $2,114 $514 $143–$1,391 $149
2023 $2,887 $607 $159–$1,674 $160
2024 $14,769 $751 $204–$1,903 $164
2025 $31,091 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Galderma Laboratories, L.P. $40,291 66 payments
  2. AbbVie, Inc. $3,103 158 payments
  3. Regeneron Healthcare Solutions, Inc. $1,325 68 payments
  4. UCB, Inc. $1,109 74 payments
  5. Novartis Pharmaceuticals Corporation $1,012 30 payments
  6. Janssen Biotech, Inc. $1,003 35 payments
  7. Genzyme Corporation $956 35 payments
  8. Pfizer Inc. $705 39 payments
  9. E.R. Squibb & Sons, L.L.C. $702 37 payments
  10. Sun Pharmaceutical Industries Inc. $630 31 payments
  11. Other $3,105 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,850 10 payments
  2. Food and Beverage $15,064 671 payments
  3. Travel and Lodging $2,337 6 payments
  4. Education $429 6 payments
  5. Honoraria $260 2 payments
Products named General payments · program years 2019–2025
  1. NEMLUVIO $24,432 20 payments
  2. RINVOQ $1,585 87 payments
  3. DUPIXENT Immunology $1,426 43 payments
  4. SKYRIZI $1,077 50 payments
  5. TREMFYA $883 27 payments
  6. DUPIXENT Inflammation And Immunology $881 49 payments
  7. Bimzelx $744 50 payments
  8. SOTYKTU $702 37 payments
  9. HUMIRA $629 30 payments
  10. COSENTYX $579 23 payments
  11. Other $7,103 322 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,215

Median for Dermatology: 534

Drug cost

$351,814

Median for Dermatology: $67,151

Branded share of claims

10.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 37 $139,569
Otezla Apremilast Brand 20 $96,157
Dupixent Syringe Dupilumab Brand 16 $62,965
Opzelura Ruxolitinib Phosphate Brand 11 $21,453
Clobetasol Propionate Generic 253 $9,927
Tacrolimus Generic 30 $4,879
Fluorouracil Generic 73 $4,832
Triamcinolone Acetonide Generic 228 $2,060
Doxycycline Hyclate Generic 79 $1,734
Ketoconazole Generic 106 $1,639

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$88,928

Of which drugs: $367

Medicare patients

447

Average age 74

Services billed

1,983

272 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 45%
Diabetes 26%
Ischemic heart disease 24%
Chronic kidney disease 21%
Depression 19%
Atrial fibrillation 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 77 $56

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$510 53 —
Bimzelx
$402 — —
RINVOQ
$379 — —
COSENTYX
$329 — —
Zoryve
$287 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

695 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record